Relais' Q2 adjusted EBITA came in well in line with LSEG Data & Analytics consensus expectations.
We lower 2025E adjusted EBIT by 10% yet keep 2026E-27E adjusted EBIT largely intact (+2%), as we fin...
Återhämtningen av marginalen går fortare än väntat och omsättningen är på spåret.
- Earnings disappointment in Q2, but strong cash flow - We lower our US and Germany EBIT estimates -...
Voi, som är VNV Globals näst största innehav, kom med en mycket stark Q2-rapport.
Redeye comments on Bredband2’s Q2 report which posted marginally stronger performance across the boa...
Relais Q2 adjusted EBITA of EUR 7.6m was up 3% y/y and came 2% above LSEG Data & Analytics consensus...
Redeye retains its positive view of Transtema following a Q2 report that aligns with our expectation...
Redeye comments on Embracer’s Q1-results which were weaker than expected, owing mainly to soft perfo...
Redeye provides an update on Scandinavian ChemoTech following the Q2 2025 report.
Redeye comments on the SEK2.2m milestone bonus payment received for a game under a work-for-hire agr...
Taaleri's Q2 results came largely in line with our expectations on an underlying basis, owing to goo...
EQL Pharma redovisade ökad nettoomsättning och EBIT i det första kvartalet.
EBIT -9% vs cons, -15% vs ABGSC Order backlog +25%, organic growth +43% y-o-y We expect limited esti...
Margin upside building into H2 We cut EBITDA by 9-4% for '25e-'27e Trading at ~22x '26e EV/EBITDA F...
Q2'25e organic sales growth of 45% y-o-y We raise '25e paying users by 2% FVR of SEK 30-45 reiterate...
Taaleri’s continuing earnings of EUR 10.6m increased by 6% y/y and were 8% above our estimate.
Redeye updates in Better Collective ahead of Q2-results (due 20 August after market close) where we ...
Redeye updates its view on Genovis' following a Q2 2025 report falling slightly short of our estimat...
Raute’s margins impress, while extended low orders pose big earnings headwinds, yet multiples remain...
